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Deletions at 16p13.11 are associated with schizophrenia, mental retardation, and most recently idiopathic generalized epilepsy. To
evaluate the role of 16p13.11 deletions, as well as other structural variation, in epilepsy disorders, we used genome-wide screens to
identify copy number variation in 3812 patients with a diverse spectrum of epilepsy syndromes and in 1299 neurologically-normal
controls. Large deletions (> 100 kb) at 16p13.11 were observed in 23 patients, whereas no control had a deletion greater than 16 kb.
Patients, even those with identically sized 16p13.11 deletions, presented with highly variable epilepsy phenotypes. For a subset of
patients with a 16p13.11 deletion, we show a consistent reduction of expression for included genes, suggesting that haploinsufﬁciency
might contribute to pathogenicity. We also investigated another possible mechanism of pathogenicity by using hybridization-based
capture and next-generation sequencing of the homologous chromosome for ten 16p13.11-deletion patients to look for unmasked reces-
sive mutations. Follow-up genotyping of suggestive polymorphisms failed to identify any convincing recessive-acting mutations in the
homologous interval corresponding to the deletion. The observation that two of the 16p13.11 deletions were larger than 2Mb in size led
us to screen for other large deletions.We found 12 additional genomic regions harboring deletions> 2Mb in epilepsy patients, and none
in controls. Additional evaluation is needed to characterize the role of these exceedingly large, non-locus-speciﬁc deletions in epilepsy.
Collectively, these data implicate 16p13.11 and possibly other large deletions as risk factors for a wide range of epilepsy disorders, and
they appear to point toward haploinsufﬁciency as a contributor to the pathogenicity of deletions.Introduction
Although common SNPs have been shown to play at most
a modest role in most neuropsychiatric diseases, a growing
body of evidence connects large deletions and duplica-
tions, or copy number variants (CNVs), to schizophrenia,
autism, and mental retardation.1–5 Recently, deletions at
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The Amephrenia2 and mental retardation,6 have now been associ-
ated with idiopathic generalized epilepsy.7,8 These ﬁndings
add epilepsy to the growing list of neuropsychiatric condi-
tions with overlapping susceptibility conferred by copy
number variation.
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generalized seizure disorders. We also explore possible
mechanisms of pathogenicity for large deletions in neuro-
psychiatric disease.Subjects and Methods
Subjects
Patients with either focal (> 90%) or generalized epilepsy were
drawn fromfour sitesmakingup theEPIGENConsortium(Brussels,
Belgium [n ¼ 550]; Dublin, Ireland [n ¼ 624]; Durham, NC, USA
[n ¼ 755]; and London, UK [n ¼ 1237]), with additional cohorts
from the GenEpA Consortium (Finland [n ¼ 417], Switzerland
[n¼ 229]). All patients were asked to participate in a study investi-
gating the genetics of epilepsy during routine clinical appoint-
ments at each site, in accordance with institutional standards. All
patients had a deﬁnite diagnosis of epilepsy according to Interna-
tional League Against Epilepsy (ILAE) deﬁnitions. Seizure types
and epilepsy syndromes were classiﬁed according to the ILAE
classiﬁcations. DNA was extracted from primary (untransformed)
cells from either a blood (n ¼ 3729) or brain (n ¼ 63) sample. No
recruited patients with neuropsychiatric disease and/or mental
retardationwere excluded if theymet the criteria of having a genet-
ically unexplained seizure disorder. Information about family
history was provided by the patient, but blood samples for DNA
wereobtainedonly fromconsenting familymembers if theprimary
patient had a putative epilepsy-associated deletion and the indi-
vidual consented to the follow-up investigations.
For comparison, we used controls from Finland and Switzerland
who had no neuropsychiatric condition (n¼ 546). In addition, we
evaluated 755 cognitively normal control subjects who had taken
part in the Genetics of Memory study at Duke University and had
undergone cognitive testing. These subjects were used to assess the
frequency of epilepsy-associated deletions in controls and to assess
the effects of epilepsy-associated CNVs on cognitive function.
DNA from control subjects was obtained from blood (n ¼ 52) or
saliva (n ¼ 1247). Controls used in this study partially overlap
controls used in the Need et al. 2009 schizophrenia (SCZD [MIM
181500]) study.2 A total of 753 controls overlapped with this
study; there were 546 unique controls evaluated here and 840
unique neuropsychiatrically normal controls evaluated in Need
et al.2 In some cases, patients were recontacted with a request
for additional blood samples from family members, blood samples
for expression assessments, and additional blood samples for DNA
when necessary. We were successful in obtaining additional
samples only in a subset of patients.
All phenotypic data and samples were collected in accordance
with the ethical standards set forth by the Duke University Institu-
tional Review Board, Durham, NC, USA; Ethics Committee Erasme
Hospital and Ethics Committee Gasthuisberg, Brussels, Belgium;
Joint Research Ethics Committee of the National Hospital for
Neurology and Neurosurgery and the Institute of Neurology, Lon-
don, UK; Kantonale Ethik-Kommission, Zurich, Switzerland; Beau-
montHospital EthicsCommittee,Dublin, Ireland; and theAdvisory
Board on Health Care Ethics, Sub-Committee on Medical Research
Ethics, Helsinki, Finland.
Genome-wide Genotyping
DNA from all individuals were genotyped on the Illumina Human
610-Quad genome-wide genotyping array, with the exception of
a subset run on other chips, including HumanHap 1M (n ¼ 4),
HumanHap 550K (n ¼ 131), and HumanHap 317K (n ¼ 47). All708 The American Journal of Human Genetics 86, 707–718, May 14,samples were genotyped in the Institute for Genome Sciences &
Policy Genotyping Facility, and quality control measures were
standardized across all batches.
CNV Calling
The CNV calls were generated with the PennCNV software
(version 2008 June 26), with the use of the log R ratio (LRR) and
B allele frequency (BAF) for all SNPs and CNV probes included
on the genotyping chips. Standard PennCNV quality control
checks were used for excluding unreliable samples, including
LRR standard deviation (SD) greater than 0.28, BAFmedian greater
than 0.55 or less than 0.45, BAF drift greater than 0.002, or a wavi-
ness factor of greater than 0.04 or less than 0.04. Individual
CNVs were excluded if the PennCNV-generated conﬁdence score
was less than 10, if they were called on the basis of fewer than
ten SNPs or CNV probes, if the CNV spanned a centromere, and,
ﬁnally, if the CNVs overlapped at least 50% with regions previ-
ously described as being prone to false positives due to somatic
mutations.2
Deletions greater than 1 Mb and speciﬁc regions associated with
epilepsy were visually inspected in Illumina Beadstudio for calling
accuracy. Speciﬁcally, in cases of a subject having two or more
CNVs called within 1 Mb of each other, the uncalled region was
inspected for the genotyping quality. If only SNPs that failed gen-
otyping quality control were used to establish a break in the CNV,
it was assumed to be continuous.
Conﬁrmation of a Subset of Deletions
Deletions were conﬁrmed in a subset of patients via comparative
genomic hybridization (CGH) (Roche Nimblegen, HG18 WG
Tiling CGH 2.1M v2). Deletions at 16p13.11 were conﬁrmed via
quantitative real-time PCR ampliﬁcation of genomic DNA. Stan-
dard protocol was used for ampliﬁciation, with b-globin used as
an internal reference. In brief, multiplex 10 ml reactions contain-
ing a ﬁnal concentration of 900 nM of each primer [ (b-globin
[forward: 50-GGCAACCCTAAGGTGAAGGC-30, reverse: 50-GGTGA
GCCAGGCCATCACTA-30]; 16p13.11 [forward: 50-GATCAGTCCC
CAAACCGAAC-30, reverse: 50-CGCCATCTCTGTTCTTGCTG-30]),
250 nM of each ﬂuorescently labeled probe (b-globin: VIC,
50-CATGGCAAGAAAGTGCTCGGTGCCT-30; 16p13.11: FAM,
50-AGGTGGCCCAGCCTCTGGGC-30), and 10 ng of genomic
DNAwere run in duplicate (TaqmanUniversal mastermix, Applied
Biosystems [PCR conditions: 50C 3 2 min, 95C 3 10 min,
40 cycles of 95C 3 15 s, 60C 3 1 min, then 4C]). A standard
curve was constructed for b-globin and the locus within
16p13.11 on the basis of the number of cycles needed to achieve
a threshold ﬂuorescence for ﬁxed amounts of DNA from subjects
with two copies 16p13.11 (based on PennCNV calls), ranging
from 0.25 to 200 ng. Relative copy number in the test sample
was estimated by extrapolating from the standard curves an esti-
mated DNA amount at each locus on the basis of the number of
cycles needed to reach the deﬁned threshold for that sample,
then taking a ratio (16p13.11/b-globin). An average ratio, with
an associated coefﬁcient of variation between replicates of less
than 25%, of greater than 0.25 and less than 0.75 was considered
to be a single-copy deletion at 16p13.11. Correspondingly, a two-
copy state at the 16p13.11 locus was called if the ratio was greater
than 0.75 and less than 1.25.
Expression Analyses in Blood Samples
Blood samples from a subset of patients with epilepsy-associated
deletions were studied for effects on gene expression. Blood was2010
collected in Tempus tubes (Applied Biosystems) and extracted via
a standard protocol. Quality of RNA was assessed on an Agilent
Bioanalyzer. Gene transcript levels were estimated with Illumina
Human HT-12 v3 microarrays (standard protocols). Data were
normalized via robust spline normalization in R (v2.8.0). Only
transcripts whose normalized expression in a set of n ¼ 8 controls
exceeded the mean normalized expression values across all tran-
scripts evaluated on the array were included in this analysis,
ensuring the highest sensitivity for detection of an effect. Data
generated in this experiment is publically available through
Gene Expression Omnibus (accession number GSE20977).
Deletion Inheritance
When available, blood samples were obtained from family
members, and DNA was extracted and analyzed on the Illumina
610-Quad genotyping array. The relevant regions were visually
inspected (in Beadstudio) and statistically assessed in PennCNV
for ascertainment of copy number status. Relationships were
conﬁrmed with the use of genome-wide SNP-genotyping data.
Capture and Next-Generation Sequencing
of the 16p13.11 Locus in Patients with a Deletion
A 3.3 Mb region spanning the deleted interval located at 16p13.11
was captured via an in-solution method (Agilent SureSelect). The
captured intervals excluded large nongenic regions and included
the following positions along chromosome 16 (chr16): 14380454–
16405334, 16572078–16574838, 16658507–16666547, 17015093–
17482240, and18309264–18762264 (NCBIBuild 36.1). The isolated
region was sequenced in a single lane on the Illumina Genome
Analyzer. The sequencing reads (two paired-end 75 bp fragments)
were aligned to reference with the use of BWA software.9 SAMTools
software was used to call SNP and indel variants.10 Variants were
considered only if they had a consensus and SNP quality exceeding
20, if there were at least three reads supporting the variant, and
if they were located within the PennCNV-estimated deletion
boundaries.Results
Evaluation of 15q13.3 and 16p13.11
Epilepsy-Associated Risk Loci
First, we evaluated three epilepsy-risk loci previously impli-
cated in idiopathic generalized forms of epilepsy:
15q13.3,7,11 15q11.2,8 and 16p13.11.2,8 We observed one
patient with a deletion spanning 15q13.3 (15q13.2–
q13.3, Table 1). Consistent with previous reports, this
patient has a diagnosis of juvenile myoclonic epilepsy
(Table S1, available online), a form of idiopathic general-
ized epilepsy. The absence of 15q13.3 deletions in any of
the more than 3000 focal epilepsy patients suggests that
its involvement in epilepsy disorders is speciﬁc to general-
ized forms, despite the fact that deletions in this region
have been associated with nonspeciﬁc effects in neuropsy-
chiatric disease risk.3,7,12
At the second epilepsy-risk locus, 15q11.2,8 we observed
24 patients and three controls with a deletion larger than
300 kb (one-sided Fisher’s exact test, p ¼ 0.06). Two addi-
tional cases and three controls had smaller deletions in
the region (< 100 kb). Two of the 24 patients (~8%) withThe Amea deletion greater than 300 kb in the previously reported
risk region had a diagnosis of generalized epilepsy, which
is approximately equal to the percentage of patients with
generalized epilepsy disorders in the cohort studied. In
our analysis, this region does not appear to be clearly
associated with partial or generalized epilepsy.
At the epilepsy-associated 16p13.11 locus, we found 23
patients with deletions greater than 100 kb in the region,
whereas the largest deletion in controls in this region is
16 kb (Figure 1, one-tailed Fisher’s exact test, p ¼ 0.001).
Although the deletions in epilepsy patients apparently
vary in size, all but three cover a core set of seven genes,
including NDE1 (MIM 609449, Figure 1), a gene with sus-
pected involvement in human cortical development.13
Interestingly, we do not see any straightforward pheno-
typic similarities within the set of patients with 16p13.11
deletions, even among identically sized deletions (Table 2),
including instances of both partial and generalized
epilepsy. We also see no increased frequency of psychiatric
illness in patients with 16p13.11 deletions, though such
an increase might have been expected given the reported
role of this deletion in schizophrenia.2 Psychiatric pheno-
types were observed in only four out of 23 patients, which
does not exceed the rate of psychiatric comorbidities in the
general epilepsy patient population.14 All patients with
a 16p13.11 deletion were adults (>18 yrs of age). Finally,
16p13.11 deletions have previously been associated with
mental retardation or multiple congenital abnormalities
(MR/MCA), with epilepsy reported in approximately 25%
of MR/MCA patients.6 Although some of the patients
have the clinical impression of lower than average intelli-
gence quotients and dysmorphism (Table 2), none have
MR/MCA.
Conﬁrmation of 16p13.11 Deletions
The DNA from one patient with a 16p13.11 deletion was
analyzed via CGH (Figure 2A). The deletion was conﬁrmed
on the CGH array; however, the deletion boundaries were
found to be larger (Figure 2A, chr16: 15.2–16.6, 1.4 Mb)
than those inferred by PennCNV (chr16: 15.4–16.2, 811
kb). The extended boundaries estimated by CGH did not
alter the genic content of the deletion. Additional conﬁr-
mation of 16p13.11 deletions was also performed,
including replication of the original PennCNV calls by re-
genotyping in a subset (Figure 2B) and by directly conﬁrm-
ing the overall association statistics for the 16p13.11
region via quantitative real-time PCR in genomic DNA
(Figure 2C).
Inheritance Patterns of 16p13.11 Deletions
We also investigated inheritance patterns for two individ-
uals carrying 16p13.11 (n ¼ 2) deletions by evaluating
the CNV status at 16p13.11 in trios involving both parents
of the proband. In one trio the deletion was de novo,
whereas for the other proband the deletion was inherited
from the mother (Table 2). In addition to the two trios,
we also observed two other maternally inherited deletionsrican Journal of Human Genetics 86, 707–718, May 14, 2010 709
Table 1. List of Heterozygous Deletions Greater than 1 Mb Observed in Epilepsy Patients
Cytoband Size (Mb) Gene Lista
1p21.2–p21.1 5.6 EDG1, AMY1C, AMY1B, AMY1A, SLC35A3,COL11A1,VCAM1, LRRC39, RNPC3, SLC30A7, RTCD1,DBT, AMY2B, AMY2A,
AGL, CCDC76, DPH5, HIAT1, PALMD, AL359760.10, OLFM3, CDC14A, SASS6, EXTL2, GPR88, FRRS1, AL356280.21
1q21.1b 1.2 AL139152.7, ACP6, BCL9, GJA8, GJA5, RP11-94I2.2, FMO5, AL049742.8, FAM108A3, CHD1L, PRKAB2, AL356004.9
1q21.1b 1.1 AL139152.7, ACP6, BCL9, GJA8, GJA5, RP11-94I2.2, FMO5, AL049742.8, FAM108A3, CHD1L, PRKAB2
3q11.2 4.3 ARL6, OR5H1, AC110491.5, AC026100.19, AC024218.17, DHFRL1, STX19, NSUN3, PROS1, MINA, EPHA6, ARL13B,
OR5AC2
4q32.3 1.2 SPOCK3
4q35.1–q35.2 1.5 F11, AC096659.1, SORBS2, PDLIM3, TLR3, KLKB1, FAT, FAM149A, MTNR1A, CYP4V2
4q35.2c 1.97 AC093909.2, AC020698.4, TRIML2, TRIML1, ZFP42
5q12.3–q13.2c 6.1 MAST4, OCLN, PMCHL2, AC146944.1, CCNB1, CCDC125, CENPH, CD180, SMN2, SMN1, SFRS12,MCCC2, AC145102.2,
MRPS36, AC131392.2, AC139277.2, AC139834.2, AC145146.2, TAF9, AC145132.2, GTF2H2, CDK7, BDP1, MRPS27,
MAP1B, SLC30A5, CARTPT, AC140134.2, MARVELD2, RAD17, NAIP, SERF1A, AC145138.2, AC092373.2, AC139495.2,
PIK3R1, AC139272.3
5q15 1.4 RIOK2, LIX1, LNPEP, PCSK1, ARTS-1, CAST, ELL2, LRAP
5q23.1 1 None
5q34 3 MAT2B, GABRB2, GABRA6, HMMR, NUDCD2, ATP10B, GABRG2, GABRA1, CCNG1, GLRXL
6q12 5.2 AL450394.9, BAI3, AL356454.15, AL445677.1, AL109922.9, AL450324.10, EGFL11, AL365217.10, EGFL10
7q21.11–q21.13 12 SEMA3A, AC002064.2, GRM3, PCLO, GNAI1, GTPBP10, STEAP4, MAGI2, RUNDC3B, SRI, STEAP2, STEAP1, CLDN12,
ABCB4,DBF4, ABCB1, CROT, SLC25A40, ZNF804B, ADAM22,HGF, C7orf23, AC004082.1,DMTF1, KIAA1324L, TP53AP1,
AC002081.1, PFTK1, AC002127.1, CD36, CACNA2D1, GNAT3, SEMA3E, SEMA3D, SEMA3C
7q31.32–q31.33 2.9 AP4M1, POT1, GPR37, SPAM1, HYAL4, GRM8
8q11.22–q11.23 2 AC012413.10, SNTG1
9p23 1.1 None
9p24.3–p23 9.8 INSL6, INSL4, AL583805.7, KIAA0020, VLDLR, KANK1, SLC1A1, CDC37L1, AL353638.15, ERMP1, RANBP6, PPAPDC2,
CD274, RFX3, SMARCA2, KCNV2, UHRF2, GLDC,MLANA, AK3, TPD52L3, AL365202.19,DMRT3, AL161450.14,DMRT2,
DMRT1, RCL1, JMJD2C, C9orf46, AL354941.10, GLIS3, KIAA1432, C9orf123, JAK2, PTPRD, KIAA2026, RLN2, RLN1,
C9orf68, IL33, DOCK8, C9orf66, PDCD1LG2
10q11.21–q11.23c 5.6 AL591684.7, CHAT, LRRC18, AC027674.10, MSMB, ANXA8L2, ANXA8L1, TIMM23, ANXA8, AL603966.9, NCOA4,
C10orf73, C10orf72, MAPK8, TIMM23B, C10orf71, FRMPD2, AL672187.12, FRMPD2L2, DRGX, OGDHL, PPYR1, RBP3,
AL954360.3, AL450334.15, AL356056.22, CTGLF5, CTGLF4, CTGLF3, AL391137.11, PTPN20B, PTPN20A, SYT15,
CTGLF2, C10orf64, ARHGAP22, AL603965.10, BX649215.1, PDZD5A, PARG, C10orf128, PGBD3, GDF10, GDF2,
C10orf53, ANTXRL, AL442003.8, GPRIN2, AL731733.9, ZNF488, SLC18A3
12p13.32–p13.31 1.6 KCNA5, NDUFA9, RAD51AP1, KCNA1, AC007848.11, DYRK4, NTF3, VWF, GALNT8, FGF6, AC008012.8, AKAP3, KCNA6,
TMEM16B
13q21.32–q21.33 4.6 KLHL1, PCDH9
15q11.2 1.3 AC025884.28, AC026495.13, OR4N4, OR4M2, AC131280.9, AC134980.3, AC126335.16, A26B1
15q11.2 1 AC025884.28, OR4N4, OR4M2, AC131280.9, AC134980.3, AC126335.16, A26B1
15q13.2–q13.3 1.5 CHRNA7, MTMR15, MTMR10, AC004460.1, TRPM1, ARHGAP11B, KLF13, OTUD7A
16p12.3 1.5 AC109446.2, XYLT1
16p13.11 1.2 ABCC6, KIAA0430, ABCC1, AC130651.2, NDE1, C16orf45, MPV17L, MYH11, C16orf63, RRN3, NTAN1, PDXDC1
16p13.11 1.2 NDE1, C16orf45, KIAA0430, AC130651.2, ABCC1, MYH11, C16orf63, RRN3, NTAN1, PDXDC1, ABCC6
16p13.11 1.2 ABCC6, KIAA0430, ABCC1, AC130651.2, NDE1, C16orf45, MPV17L, MYH11, C16orf63, RRN3, NTAN1, PDXDC1
16p13.11–p12.3c 2.7 ABCC6, KIAA0430, ABCC1, AC130651.2, NDE1, XYLT1, C16orf45, MPV17L, MYH11, NOMO3, AC136619.3, C16orf63,
AC138969.2, AC109446.2
16p13.11–p12.3c 2.9 ABCC6, KIAA0430, ABCC1, AC130651.2, NDE1, XYLT1, C16orf45, MPV17L, MYH11, NOMO3, AC136619.3, C16orf63,
AC138969.2, AC109446.2
17p12d 1.4 AC005838.2, FAM18B2, AC005863.1, HS3ST3B1, COX10, TEKT3, CDRT4, PMP22, CDRT15
17p12 1.4 PMP22, CDRT15, TEKT3, COX10, HS3ST3B1, CDRT4, AC005863.1, FAM18B2
17p12 1.4 AC005838.2, FAM18B2, AC005863.1, HS3ST3B1, COX10, TEKT3, CDRT4, PMP22, CDRT15
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Table 1. Continued
Cytoband Size (Mb) Gene Lista
17q12e 1.4 LHX1, AP1GBP1, ZNHIT3, PIGW, C17orf78, HNF1B, AC003042.2, MYO19, DUSP14, MRM1, DDX52, TADA2L, ACACA,
AATF, ZNF403
18p11.32–p11.31 5 THOC1, EMILIN2, KNTC2, AP002478.3, TGIF,f TYMS, C18orf56,DLGAP1, ENOSF1, SMCHD1,CLUL1,METTL4, COLEC12,
CETN1, MYOM1, YES1, USP14, LPIN2, AP001011.6, C18orf2, AP005329.2, ADCYAP1, AP005329.1
19p12 1 AC024563.6, AC011467.7, ZNF98, AC022145.8, ZNF208, ZNF257, ZNF676, AC008626.6
19p12 1 AC024563.6, AC011467.7, ZNF98, AC022145.8, ZNF208, ZNF257, ZNF676, AC008626.6
Deletions observed in controls include 1q21.1 (chr1: 144838594–145848182), 14q31.3 (chr14: 86328510–87722142), and 18p11.32 (chr18:
755920–2473514).
a Fully and partially included genes based on PennCNV-inferred boundaries and the Ensembl database.
b Similarly sized deletion observed in a neurologically normal control.
c Boundaries redefined with visual inspection (see Subjects and Methods).
d Deletion identified in brain tissue specimen procured during therapeutic lobectomy.
e Similarly sized duplications were also observed exclusively in cases.
f No malformation observed on brain MRI.at 16p13.11 in probands for which only the maternal
sample was available (Table 2). In the three cases of
inherited 16p13.11 deletions, the parent carriers are unaf-
fected by epilepsy, but no neuropsychiatric testing was
carried out on these individuals.
Mechanistic Evaluation of 16p13.11 Deletions
Expression Consequences of 16p13.11 Deletions in Lymphocytes
For seven of the 23 patients with 16p13.11 heterozygous
deletions, we evaluated the effect of the deletion on gene
expression of genes included in and nearby the deletion
in lymphocytes. We extracted RNA from whole-blood
samples of patients with deletions and measured transcrip-
tome-wide expression. We evaluated two groups of genes
in this analysis: (1) all genes within 1 Mb of theMKL2
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Figure 1. 16p13.11 Deletions Observed Exclusively in Epilepsy Pat
A total of 23 deletions were observed in the region (indicated by blue b
sharing a common segment including or disrupting the NDE1 gen
separated only by SNPs that failed genotyping quality control were a
bar in this display). Using the exact same criteria in controls, we obser
the boundaries of these deletions are shown.
Figure produced in part with the use of the UCSC Genome Browser.
The AmePennCNV-inferred deletion boundary but not included
within it (‘‘nearby’’ genes), and (2) genes included in
each deletion (genes that are partly or entirely deleted).
We used control samples with no 16p13.11 deletion
(n ¼ 8) to calculate SD for the distribution of gene expres-
sion for all highly expressed (expressed at level greater than
the control group average) ‘‘nearby’’ and ‘‘included’’ genes
for each deletion. We then determined, for each nearby
and included transcript, the distance from the mean in
SD units. All three highly expressed transcripts included
within the PennCNV-estimated boundaries show a clear
reduction in expression: C16orf63 (two-sided t test, p¼ 13
106), KIAA0430 (p ¼ 0.006), and NDE1 (p ¼ 5 3 105
[MIM 609449]) (Figure 3). No effects of the 16p13.11 dele-
tions were detected in any nearby transcripts (Figure 3).XYLT1 NOMO2
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ARL6IP1
TMC7
COQ7
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17,000,000 18,000,000
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ars marking the locations of patient-speciﬁc deletions), 22 of them
e. Deletions in the same patient that were called in tandem and
ssumed to be continuous and merged together (shown as a single
ved no deletions exceeding 16 kb. Segmental duplications ﬂanking
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Table 2. Clinical Characteristics of Patients with a 16p13.11 Deletion
Chr16 Position
(PennCNV) (Mb)
Size of
Event
(Mb) Descent Syndrome Seizure Types MRI Drug Responsiveness
Deletion Acquisition/
Seizure-Related
Family History
Cognitive and/or
Psychiatric
Comorbidities,
Dysmorphism
15.70–15.86 0.2 British partial epilepsy, focus
unknown, cryptogenic
CPS, SGTCS normal seizure-free on
monotherapy
unknown/none obsessive-compulsive
disorder, no cognitive or
other psychiatric disorder.
15.44–16.20a,b 0.8 North American,
European
juvenile absence
epilepsy
absences, GTCS normal seizure-free on
dual therapy
inherited from
mother/grandparent
with epilepsy
no indication for cognitive/
psychiatric testing
15.39–16.19a,b 0.8 Mizrahi Jewish partial epilepsy, focus
unknown, cryptogenic
SPS, CPS, SGTCS normal seizure-free on
monotherapy
inherited from
mother/family history
of febrile seizures
obsessive-compulsive
disorder, learning disability,
VIQ 77, PIQ 62
15.39–16.19 0.8 North American,
European
unclassiﬁed
epilepsy
Dialeptic seizures,
myoclonic seizures,
GTCS
unilateral parietal
encephalomalacia
refractory unknown/none no indication for cognitive/
psychiatric testing
15.39–16.20c 0.8 Northwest
European
childhood absence
epilepsy
Absences aspeciﬁc white
matter lesions
refractory unknown/mother
and two maternal
cousins with epilepsy
no indication for cognitive/
psychiatric testing
15.39–16.20 0.8 Italian frontal lobe epilepsy,
symptomatic
CPS, SGTCS extensive right
frontal cystic
encephalomalacia
several seizure-free
periods of ~1 year,
but not currently
seizure-free
unknown/none Gilles de la Tourette
syndrome, no indication
for cognitive testing
15.39–16.20c 0.8 North American,
European
juvenile absence
epilepsy
Absences, GTCS normal refractory unknown/none no indication for cognitive/
psychiatric testing
15.39–16.20 0.8 British temporal lobe epilepsy,
cryptogenic
SGTCS normal refractory unknown/none no indication for cognitive/
psychiatric testing
15.39–16.20c,d 0.8 Finnish temporal lobe epilepsy,
cryptogenic
SGTCS normal refractory unknown/data
unavailable
no indication for cognitive/
psychiatric testing
15.39–16.20c 0.8 Irish temporal lobe epilepsy,
symptomatic
SPS, CPS, SGTCS postoperative
signal changes
in white matter
refractory unknown/none low-normal cognitive
function, VIQ 82, PIQ 76.
No psychiatric disorders.
15.39–16.20a,b,e 0.8 North American,
European
unclassiﬁed epilepsy GTCS normal refractory inherited from
mother/none
no indication for cognitive/
psychiatric testing, Streeter’s
bands and syndactyly
15.39–16.20a,b 0.8 North American,
European
unclassiﬁed epilepsy Dialeptic seizures,
GTCS
normal refractory did not inherit from
mother, paternal
transmission
unknown/none
no indication for cognitive/
psychiatric testing. Clinical
impression of low-normal
IQ, mild dysmorphism
15.37–16.19 0.8 British partial epilepsy,
focus unknown,
cryptogenic
CPS normal seizure-free on
dual therapy
unknown/strong family
history of epilepsy, several
affected members on both
paternal and maternal
sides of family
no indication for cognitive/
psychiatric testing
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Table 2. Continued
Chr16 Position
(PennCNV) (Mb)
Size of
Event
(Mb) Descent Syndrome Seizure Types MRI Drug Responsiveness
Deletion Acquisition/
Seizure-Related
Family History
Cognitive and/or
Psychiatric
Comorbidities,
Dysmorphism
15.37–16.20c 0.8 Northwest
European
temporal lobe
epilepsy,
cryptogenic
SPS, SGTCS normal refractory unknown/none no indication for cognitive/
psychiatric testing
15.39–16.23c 0.8 British temporal lobe epilepsy,
cryptogenic
SPS, CPS, SGTCS normal refractory unknown/two
maternal sibs with
epilepsy
psychotic depression
postdating onset of
epilepsy
15.39–16.23 0.8 African descent temporal lobe epilepsy,
symptomatic
CPS HS refractory unknown/none no cognitive or
psychiatric disorder
15.35–16.20c,d 0.8 Northwest
European
temporal lobe epilepsy,
symptomatic
SPS, CPS, SGTCS HS, nonspeciﬁc
white matter
changes
refractory unknown/none no indication for cognitive/
psychiatric testing
15.02–16.19c 1.2 British frontal lobe epilepsy,
cryptogenic
CPS, SGTCS nonspeciﬁc bilateral
periventricular white
matter changes
refractory unknown/two paternal
relatives with epilepsy
normal cognitive function,
psychosis on topiramate but
no primary psychiatric
history
15.03–16.19a,b 1.2 African descent juvenile absence
epilepsy
Absences, GTCS normal refractory de novo/none no indication for cognitive/
psychiatric testing
15.10–16.23c,d 1.2 Irish temporal lobe
epilepsy, symptomatic
CPS, SGTCS unilateral temporal
lobe gliosis, affecting
lateral neocortex
refractory unknown/sibling with
generalized epilepsy
no indication for cognitive/
psychiatric testing
16.77–18.26c 1.5 Northwest
European
temporal lobe epilepsy,
symptomatic
SPS, CPS, SGTCS unilateral temporal stroke
and abnormal ipsilateral
hippocampal internal
structure
rare seizures off
antiepileptic drug
treatment
unknown/none cognitive problems
secondary to the venous
thrombosis (MMSE 27/30)
15.39–18.08b 2.7 Northwest
European
partial epilepsy,
focus unknown,
symptomatic
SGTCS venous sinus thrombosis
and small right frontal
subdural hematoma
seizure-free on
monotherapy
unknown/none cognitive problems
secondary to the venous
thrombosis (MMSE 28/30
and Addenbrooke 89/100)
15.39–18.26b 2.9 British temporal lobe epilepsy,
cryptogenic
SPS, CPS, SGTCS normal refractory unknown/sibling with
febrile seizures
no cognitive or
psychiatric disorder
Abbreviations are as follows: TLE, temporal lobe epilepsy; HS, hippocampal sclerosis (typical MRI with or without histological confirmation); SPS, simple partial seizures; CPS, complex partial seizures; SGTCS, secondarily
generalized tonic clonic seizures; VNS, vagal nerve stimulator.
a Evaluated in deletion-acquisition experiment.
b Evaluated in expression analyses.
c Sequenced along the intact homolog to search for deleterious recessive variants.
d Patient has a putatively functional SNP in MPV17L.
e Confirmed by array CGH.
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Figure 2. Confirmation of 16p13.11 Deletions
(A) CGH experiment conﬁrming the 16p13.11 deletion. Intensity signals in a single patient with a 16p13.11 deletion detected via
PennCNV on Illumina-based genotyping technology (top panel) compared to data collected on the same deletion patient via CGH
(Roche NimbleGen, bottom panel). Deletion regions called by the two technologies are shown in red, and the coordinates deﬁning
the start and end points of the deletions are provided above each panel.
(B) A set of 14 individuals were regenotyped on the Illumina HumanHap 610 genotyping chips for replication of initial calls. All
14 deletions replicated, and the sizes of deletions called were highly correlated.
(C) Conﬁrmation of the 16p13.11 deletion with the use of Taqman-based real-time genomic ampliﬁcation.Screen for Recessive Mutations on the Homologous Chromosome
We next sought to identify mutations present on the
homologous region of the intact chromosome that might
act as recessive risk factors for epilepsy with effects that
are ‘‘unmasked’’ by the deletion. We designed a hybridiza-
tion-based capture experiment that enriched for 2.9 Mb
within a stretch of 3.3 Mb, corresponding to ~1 Mb
surrounding the outermost PennCNV-estimated bound-
aries of deletions observed in the 16p13.11 region, large
intergenic regions excluded (Figure 4). We then isolated
this sequence in ten individuals of European ancestry
with deletions (Figure 4, Table 2) and sequenced the result
in a single lane per individual on an Illumina Genome
Analyzer. The 2.9 Mb of captured sequence was sequenced
across all individuals at an average read depth of 50 (aver-
ages within individuals ranged between 36 and 78), with
greater than 5-fold coverage for at least 93% of the
sequenced region in each subject. For CCDS (Consensus714 The American Journal of Human Genetics 86, 707–718, May 14,CoDing Sequence, National Center for Biotechnology
Information [NCBI]) genes, 96 5 1% of bases included
within exons were covered at least 5-fold, compared to <
0.1% bases covered in exons not targeted in the capture.
We then identiﬁed all putative functional single-nucleo-
tide variants (SNVs) and indels (nonsynonymous,
protein-truncating, or splice-site variants) within the
patient-speciﬁc PennCNV-estimated deletion boundaries.
We identiﬁed in total 12 SNVs and no indels meeting the
functional criteria. We then evaluated the homozygote
frequency of these 12 variants in controls by using both
the HapMap CEU population (Utah residents with
ancestry from northern and western Europe) and a set of
13 samples that have been whole-genome sequenced in
our lab for other projects. We excluded a variant as a candi-
date for conferring epilepsy risk in homozygote (or hemi-
zygote) form if its homozygote frequency in the HapMap
CEU population exceeded 5% or if two or more2010
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Figure 3. Expression Effects of a Subset of
16p13.11 Deletions in Leukocytes
(A) Shown is the number of SDs away from the group
mean for highly expressed transcripts located within
the deletion (red) and a 1 Mb surrounding region
(blue). Data are summarized for seven patients with
the 16p13.11 deletion (mean 5 standard error of
the mean) compared to eight controls.
(B) Shown is the number of SDs away from the mean
for each individual transcript evaluated in individual
subjects. The deleted region in each patient is high-
lighted in yellow. Position of the transcript along
the x axis in both panels is equal to the position of
the midpoint of the probe measuring the transcript.homozygotes were observed in the control individuals for
which whole-genome sequence was available. Of the 12
assumed functional variants identiﬁed, only four remained
after this ﬁltering process, including rs72774859 in
MPV17L, rs45511401 in ABCC1 (MIM 158343), and
SNVs located at chr16 positions 15635091 (KIAA0430)The American Journaland 15718503 (MYH11 [MIM 160745]). The
latter two variants were observed in the
same subject and were not considered likely
candidates. The MPV17L splice-site variant
(rs72774859), however, was observed in three
subjects with a consistent diagnosis of tem-
poral lobe epilepsy with secondary general-
ized tonic-clonic seizures (marked on Table 2).
We therefore genotyped this SNV in the
remaining 13 patients harboring a 16p13.11
deletion, as well as in 2997 epilepsy cases lack-
ing a deletion of 16p13.11 and in 1801 nonepi-
leptic controls. No additional patients with
a 16p13.11 deletion carried the variant on the
intact homolog. We observed ﬁve homozy-
gotes among the epilepsy cases (including
two with an incongruous phenotype) and
two homozygotes within the nonepileptic
controls. The SNV in ABCC1 (rs45511401)
was also genotyped in the larger cohort and
was likewise observed in homozygote form in
neuropsychiatrically normal controls. Collec-
tively, these data provide no evidence for the
unmasking of functional, recessive variants
contributing either to the pathogenicity or to
the pleiotropic effects of deletions at chromo-
some 16p13.11.
Enrichment of Large Heterozygous
Deletions in Epilepsy Patients
A total of six of the 23 16p13.11 deletions were
larger than 1 Mb (Table 2). To investigate
a possible class effect of deletions of this
magnitude, we screened for additional dele-
tions larger than 1Mb in patients and controls.
We found that deletions of more than 1 Mb
occurred in 36/3812 epilepsy patients butonly in 3/1299 controls (two-sided Fisher’s exact test, p ¼
0.009), whereas deletions larger than 2 Mb occurred in
14 patients and no controls (p ¼ 0.028). Most of the dele-
tions greater than 1 Mb in the epilepsy patients are
observed only once, with a total of 21 regions having
a large deletion present in only one patient in the entireof Human Genetics 86, 707–718, May 14, 2010 715
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Figure 4. Screen for Recessive Variants on the Intact Chromosome of 16p13.11
Individuals with deletions (indicated by the blue bars marking the locations of patient-speciﬁc deletions) were selected for a hybridiza-
tion-based capture and next-generation sequencing experiment in which the intact homologous stretch of chromosome corresponding
the deleted segment was sequenced in order to screen for pathogenic recessive mutations that may contribute to the risk associated with
the deletion. The average read depth averaged across all ten subjects at each base is shown, and purple bars below mark the regions
targeted in the hybridization-based capture.
Figure produced in part with the use of the UCSC Genome Browser.cohort (Table 1). Many of the genes included in the dele-
tions greater than 1 Mb are implicated in epilepsy patho-
physiology (Table 1). Of the 292 annotated genes covered
by these CNVs, three carry mutations responsible for
Mendelian epilepsies (KCNA1 [MIM 176260],15 GABRA1
[MIM 137160],16 and GABRG2 [MIM 137164]17–20),
a ﬁnding unlikely to occur by chance given a total of 13
genes known to be responsible for Mendelian forms of
idiopathic epilepsy among 23,000 genes in the genome
(p ¼ 6 3 104, binomial probability distribution). Addi-
tionally, ADAM22 (MIM 603709) is believed to interact
with the protein encoded by LGI1, encoding another
Mendelian epilepsy gene.21–23 These observations suggest
that rare deletions larger than 1 Mb may inﬂuence disease
susceptibility, a ﬁnding consistent with a recent study of
schizophrenia.2
Additional follow-up analyses of these deletion regions,
including CGH conﬁrmation (Figure S1), detailed pheno-
types of affected patients (Table S1), evaluation of deletion
acquisition in a subset of patients (Table S2), and expres-
sion changes associated with the deletions (Figure S2),
are provided online.
Genome-wide Screen for Locus-Speciﬁc CNV
Associations
Todetect smaller CNVs that associatewith epilepsy suscepti-
bility or broad categories of epilepsy subtypes, including
partial epilepsy, generalized epilepsy, or temporal lobe
epilepsy, we calculated the frequency of deletions
(copy number < 2) and duplications (copy number > 2) in
3812 patients with the epilepsy phenotype, and we
compared it to the frequency in neurologically normal
controls (n ¼ 1299). The frequency was calculated at each
uniquestart and stop site forCNVs thatmet allof thedeﬁned716 The American Journal of Human Genetics 86, 707–718, May 14,quality controlmeasures (deﬁned in Subjects andMethods).
Each site was assessed for a difference in frequency between
groups with the use of a permutation-based Fisher’s exact
test in PLINK.24 Using this approach, we detected no locus-
speciﬁc associations after correcting for multiple testing (>
32,000 tests).
Evaluation of CNV Burden in Epilepsy Patients
Finally,givenrecent reports suggestingthatCNVburden inﬂu-
ences other neuropsychiatric diseases,4,25 we also evaluated
patterns ofCNVs in epilepsypatients and controls. The results
showed no overall differences in CNV burden, average
number of genes within or disrupted by CNVs, or enhanced
presence of rare gene-disrupting CNVs as deﬁned previously
for schizophrenia.4
Discussion
Despite the increasing reports of associations of CNVs with
neurological, psychiatric, and developmental disorders,
very little is known about the functional mechanisms
that result in disease susceptibility. Even more puzzling is
the increasing evidence for complex and highly differen-
tial phenotypic consequences associated with variants in
this class.
Pathogenicity, as well as the pleiotropic consequences of
CNVs in neuropsychiatric disease, must be due to haploin-
sufﬁciency, chromatin disruption leading to diffuse expres-
sion changes in the genome, unmasking of a recessive
mutation on the intact stretch of homologous chromo-
some (previously suggested in 1), modiﬁcation of germline
or somatic mutations, epigenetic or environmental modi-
ﬁers, or a combination of two ormore of the above possible
mechanisms.2010
It is a priority for the ﬁeld to develop systematic
approaches to evaluate these and other possible models
of pathogenicity. As a ﬁrst step toward this, we have devel-
oped data addressing a subset of these mechanisms in
reference to 16p13.11 deletions, which we now clearly
associate with a wide spectrum of epilepsy disorders.
Speciﬁcally, we ﬁnd a clear reduction of gene expression
for included genes, but no systematic effects for genes
near the deleted locus (Figure 3) that might indicate an
effect on chromatin structure. In addition, at 16p13.11
we ﬁnd no obvious deleterious recessive variants on the
intact homologous chromosome in ten of the patients
carrying the deletion. For the 16p13.11 deletion, at least,
it therefore does not appear that unmasking of deleterious
recessive mutations is a major component of pathoge-
nicity. Collectively, these data seem to point tentatively
toward haploinsufﬁciency of one or more included genes
as a mechanism of pathogenicity. However, we note that
the model of haploinsufﬁciency alone would seem unable
to explain the variable presentation of deletions at
16p13.11 and those observed in other regions (1q21.11
and 15q13.33,7,12). Thus, even if haploinsufﬁciency is the
correct model, it still requires other modiﬁers to inﬂuence
the precise disease presentation.
In summary, this work suggests that 16p13.11 deletions
affect approximately 0.6% of epilepsy patients and that the
16p13.11 deletion is the most prevalent single genetic risk
factor for overall seizure susceptibility identiﬁed to date.
We also identiﬁed a number of genic regions that appear
to carry epilepsy-associated deletions and warrant detailed
evaluation as implemented here for 16p13.11 deletions.
Unraveling the interplay of functional and phenotypic
consequences of these large deletions will provide novel
insights into epilepsy pathophysiology and contribute to
an understanding of the complex genetic architecture
and phenotypic diversity within epilepsy and, likely, other
neuropsychiatric diseases.Supplemental Data
Supplemental Data include two ﬁgures and two tables and can be
found with this article online at http://www.ajhg.org.Acknowledgments
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